199 related articles for article (PubMed ID: 16518134)
1. Current therapeutic options in severe Guillain-Barré syndrome.
Shahar E
Clin Neuropharmacol; 2006; 29(1):45-51. PubMed ID: 16518134
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
Kuwabara S
Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
[TBL] [Abstract][Full Text] [Related]
3. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
Eur J Neurol; 2023 Dec; 30(12):3646-3674. PubMed ID: 37814552
[TBL] [Abstract][Full Text] [Related]
4. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
J Peripher Nerv Syst; 2023 Dec; 28(4):535-563. PubMed ID: 37814551
[TBL] [Abstract][Full Text] [Related]
5. Clinical, electrophysiological findings and evaluation of prognosis of patients with Guillain-Barré syndrome.
Kılıç B; Güngör S; Özgör B
Turk J Pediatr; 2019; 61(2):200-208. PubMed ID: 32077646
[TBL] [Abstract][Full Text] [Related]
6. [History of Guillain-Barré Syndrome].
Kusunoki S
Brain Nerve; 2015 Nov; 67(11):1295-303. PubMed ID: 26560944
[TBL] [Abstract][Full Text] [Related]
7. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Hughes RA; Wijdicks EF; Barohn R; Benson E; Cornblath DR; Hahn AF; Meythaler JM; Miller RG; Sladky JT; Stevens JC;
Neurology; 2003 Sep; 61(6):736-40. PubMed ID: 14504313
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Guillain-Barré syndrome.
McNair ND
J Infus Nurs; 2013; 36(6):397-400. PubMed ID: 24202119
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous immunoglobulin and plasmapheresis on nerve conduction parameters compared to the natural course of Guillain-Barré syndrome.
Kalita J; Mahajan R; Kumar M
J Clin Neurosci; 2024 Jul; 125():76-82. PubMed ID: 38759351
[TBL] [Abstract][Full Text] [Related]
10. The Guillain-Barré syndrome.
Fujimura H
Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and Guillain-Barré syndrome.
Harel M; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barré syndrome and variants.
Dimachkie MM; Barohn RJ
Neurol Clin; 2013 May; 31(2):491-510. PubMed ID: 23642721
[TBL] [Abstract][Full Text] [Related]
13. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
[TBL] [Abstract][Full Text] [Related]
14. Relapsing Guillain Barré Syndrome and nephrotic syndrome secondary to focal segmental glomerulosclerosis.
Souayah N; Cros D; Stein TD; Chong PS
J Neurol Sci; 2008 Jul; 270(1-2):184-8. PubMed ID: 18325535
[TBL] [Abstract][Full Text] [Related]
15. Management of Guillain-Barré syndrome with plasmapheresis or immunoglobulin: our experience from a tertiary care institute in South India.
Kishore CK; Vijayabhaskar J; Vishnu Vardhan R; Sainaresh VV; Sriramnaveen P; Sridhar AV; Varalaxmi B; Sandeep P; Ram R; Vengamma B; Siva Kumar V
Ren Fail; 2014 Jun; 36(5):732-6. PubMed ID: 24593239
[TBL] [Abstract][Full Text] [Related]
16. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
Dada MA; Kaplan AA
Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
[TBL] [Abstract][Full Text] [Related]
17. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin.
Buzzigoli SB; Genovesi M; Lambelet P; Logi C; Raffaelli S; Cattano D
Anaesth Intensive Care; 2010 Mar; 38(2):387-9. PubMed ID: 20369779
[TBL] [Abstract][Full Text] [Related]
19. The immunotherapy of Guillain-Barré syndrome.
Restrepo-Jiménez P; Rodríguez Y; González P; Chang C; Gershwin ME; Anaya JM
Expert Opin Biol Ther; 2018 Jun; 18(6):619-631. PubMed ID: 29681203
[TBL] [Abstract][Full Text] [Related]
20. [The effect of plasmapheresis and other immunomodulating therapies on the course of severe Guillain-Barré syndrome].
Hidasi E; Soltész P
Orv Hetil; 2001 Feb; 142(7):335-9. PubMed ID: 11243015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
